293 related articles for article (PubMed ID: 24515815)
1. Key learnings from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 in vitro assays.
LeBaron MJ; Coady KK; O'Connor JC; Nabb DL; Markell LK; Snajdr S; Sue Marty M
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):23-42. PubMed ID: 24515815
[TBL] [Abstract][Full Text] [Related]
2. The use and acceptance of Other Scientifically Relevant Information (OSRI) in the U.S. Environmental Protection Agency (EPA) Endocrine Disruptor Screening Program.
Bishop PL; Willett CE
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):3-22. PubMed ID: 24151143
[TBL] [Abstract][Full Text] [Related]
3. Key lessons from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 male and female pubertal assays.
Stump DG; O'Connor JC; Lewis JM; Marty MS
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):43-62. PubMed ID: 24510766
[TBL] [Abstract][Full Text] [Related]
4. Analysis of EPA's endocrine screening battery and recommendations for further review.
Schapaugh AW; McFadden LG; Zorrilla LM; Geter DR; Stuchal LD; Sunger N; Borgert CJ
Regul Toxicol Pharmacol; 2015 Aug; 72(3):552-61. PubMed ID: 26044367
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of EPA's Tier 1 Endocrine Screening Battery and recommendations for improving the interpretation of screening results.
Borgert CJ; Mihaich EM; Quill TF; Marty MS; Levine SL; Becker RA
Regul Toxicol Pharmacol; 2011 Apr; 59(3):397-411. PubMed ID: 21251942
[TBL] [Abstract][Full Text] [Related]
6. Chlorpyrifos: weight of evidence evaluation of potential interaction with the estrogen, androgen, or thyroid pathways.
Juberg DR; Gehen SC; Coady KK; LeBaron MJ; Kramer VJ; Lu H; Marty MS
Regul Toxicol Pharmacol; 2013 Aug; 66(3):249-63. PubMed ID: 23524272
[TBL] [Abstract][Full Text] [Related]
7. Lessons learned, challenges, and opportunities: the U.S. Endocrine Disruptor Screening Program.
Juberg DR; Borghoff SJ; Becker RA; Casey W; Hartung T; Holsapple MP; Marty MS; Mihaich EM; Van Der Kraak G; Wade MG; Willett CE; Andersen ME; Borgert CJ; Coady KK; Dourson ML; Fowle JR; Gray LE; Lamb JC; Ortego LS; Schug TT; Toole CM; Zorrilla LM; Kroner OL; Patterson J; Rinckel LA; Jones BR
ALTEX; 2014; 31(1):63-78. PubMed ID: 24114257
[TBL] [Abstract][Full Text] [Related]
8. Application of an integrated testing strategy to the U.S. EPA endocrine disruptor screening program.
Willett CE; Bishop PL; Sullivan KM
Toxicol Sci; 2011 Sep; 123(1):15-25. PubMed ID: 21642633
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of potential endocrine activity of 2,4-dichlorophenoxyacetic acid using in vitro assays.
Coady KK; Kan HL; Schisler MR; Gollapudi BB; Neal B; Williams A; LeBaron MJ
Toxicol In Vitro; 2014 Aug; 28(5):1018-25. PubMed ID: 24815817
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo and in vitro testis and ovary explants: utility for identifying steroid biosynthesis inhibitors and comparison to a Tier I screening battery.
Powlin SS; Cook JC; Novak S; O'Connor JC
Toxicol Sci; 1998 Nov; 46(1):61-74. PubMed ID: 9928669
[TBL] [Abstract][Full Text] [Related]
11. Key learnings from the Endocrine Disruptor Screening Program (EDSP) Tier 1 rodent uterotrophic and Hershberger assays.
Marty MS; O'Connor JC
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):63-79. PubMed ID: 24515841
[TBL] [Abstract][Full Text] [Related]
12. Screening Chemicals for Estrogen Receptor Bioactivity Using a Computational Model.
Browne P; Judson RS; Casey WM; Kleinstreuer NC; Thomas RS
Environ Sci Technol; 2015 Jul; 49(14):8804-14. PubMed ID: 26066997
[TBL] [Abstract][Full Text] [Related]
13. Introduction to "screening for endocrine activity-experiences with the US EPA's endocrine disruptor screening program and future considerations".
Marty S
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):1-2. PubMed ID: 24510782
[No Abstract] [Full Text] [Related]
14. An ongoing validation of a Tier I screening battery for detecting endocrine-active compounds (EACs).
O'Connor JC; Cook JC; Slone TW; Makovec GT; Frame SR; Davis LG
Toxicol Sci; 1998 Nov; 46(1):45-60. PubMed ID: 9928668
[TBL] [Abstract][Full Text] [Related]
15. On selecting a minimal set of in vitro assays to reliably determine estrogen agonist activity.
Judson RS; Houck KA; Watt ED; Thomas RS
Regul Toxicol Pharmacol; 2017 Dec; 91():39-49. PubMed ID: 28993267
[TBL] [Abstract][Full Text] [Related]
16. A predictive data-driven framework for endocrine prioritization: a triazole fungicide case study.
Paul Friedman K; Papineni S; Marty MS; Yi KD; Goetz AK; Rasoulpour RJ; Kwiatkowski P; Wolf DC; Blacker AM; Peffer RC
Crit Rev Toxicol; 2016 Oct; 46(9):785-833. PubMed ID: 27347635
[TBL] [Abstract][Full Text] [Related]
17. Assessment of in vivo assays for endocrine disruption.
Clode SA
Best Pract Res Clin Endocrinol Metab; 2006 Mar; 20(1):35-43. PubMed ID: 16522518
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of a Tier I screening battery compared to an in utero exposure for detecting the estrogen receptor agonist 17 beta-estradiol.
O'Connor JC; Frame SR; Biegel LB; Cook JC; Davis LG
Toxicol Sci; 1998 Aug; 44(2):169-84. PubMed ID: 9742655
[TBL] [Abstract][Full Text] [Related]
19. Application of Adverse Outcome Pathways to U.S. EPA's Endocrine Disruptor Screening Program.
Browne P; Noyes PD; Casey WM; Dix DJ
Environ Health Perspect; 2017 Sep; 125(9):096001. PubMed ID: 28934726
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Tier I screening approaches for detecting endocrine-active compounds (EACs).
O'Connor JC; Cook JC; Marty MS; Davis LG; Kaplan AM; Carney EW
Crit Rev Toxicol; 2002; 32(6):521-49. PubMed ID: 12487364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]